LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

Home・Aandelen Lijst・CareDx Inc

CareDx Inc

Gesloten

SectorGezondheidszorg

20.91 -2.79

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

20.39

Max

21.51

Belangrijke statistieken
By Trading Economics
Inkomsten	6.9M 2.8M
Verkoop	9.3M 118M
K/W Sectorgemiddelde	14.645 49.8
EPS	0.34
Winstmarge	2.387
Werknemers	761
EBITDA	5.6M 7.1M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+17.99% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-36M 1.1B
Vorige openingsprijs	23.7
Vorige sluitingsprijs	20.91

Nieuwssentiment

By Acuity

25%

75%

65 / 347 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Neutral Evidence

14.77 / 18.49 Steun & Weerstand

CareDx Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

6 mei 2026, 23:41 UTC

Winsten

Arm Holdings Lacks Supply to Meet Roaring Demand for New Chips -- Update

6 mei 2026, 21:40 UTC

Winsten

Nutrien Logs Higher Profit, Sales Growth in 1Q

6 mei 2026, 23:47 UTC

Marktinformatie

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

6 mei 2026, 23:34 UTC

Marktinformatie

Gold Prices Steady, Supported by Lower U.S. Treasury Yields -- Market Talk

6 mei 2026, 23:13 UTC

Winsten

Kakao 1Q Net Profit Beat FactSet-Compiled Consensus

6 mei 2026, 23:13 UTC

Winsten

Kakao 1Q Net KRW226.84B Vs. Net KRW200.33B >035720.SE

6 mei 2026, 23:12 UTC

Winsten

Kakao 1Q Oper Pft KRW211.40B Vs. Pft KRW105.40B >035720.SE

6 mei 2026, 23:11 UTC

Winsten

Kakao 1Q Rev KRW1.942T Vs. KRW1.864T >035720.SE

6 mei 2026, 23:11 UTC

Winsten

United Overseas Bank's CEO: Low Single-Digit Loan Growth Outlook for 2026 >U11.SG

6 mei 2026, 23:11 UTC

Winsten

United Overseas Bank's CEO: 2026 Outlook for Total Credit Costs at 25-30 Basis Points >U11.SG

6 mei 2026, 23:11 UTC

Winsten

United Overseas Bank's CEO: Low Single-Digit Operating Cost Growth Outlook for 2026>U11.SG

6 mei 2026, 23:11 UTC

Winsten

United Overseas Bank's CEO: 2026 Outlook for Full-Year NIM of 1.75%-1.80% >U11.SG

6 mei 2026, 23:11 UTC

Winsten

United Overseas Bank's CEO: High Single-Digit Fee Growth Outlook for 2026 >U11.SG

6 mei 2026, 23:07 UTC

Winsten

United Overseas Bank: 1Q Net Profit Decline Reflects Softer Operating Environment >U11.SG

6 mei 2026, 23:06 UTC

Winsten

United Overseas Bank 1Q Net Fee Income S$637M Vs. S$694M >U11.SG

6 mei 2026, 23:06 UTC

Winsten

United Overseas Bank 1Q Net Interest Income S$2.32B Vs. S$2.41B >U11.SG

6 mei 2026, 23:05 UTC

Winsten

United Overseas Bank 1Q Net S$1.44B Vs. Net S$1.49B >U11.SG

6 mei 2026, 23:04 UTC

Winsten

United Overseas Bank 1Q Total Income S$3.42B Vs. S$3.66B >U11.SG

6 mei 2026, 22:50 UTC

Winsten

Sarepta Stock Sinks on Earnings Beat. Elevidys Demand Faces a Reality Check. -- Barrons.com

6 mei 2026, 22:25 UTC

Marktinformatie

Canada's Public Finances on Sustainable Path, BOC's Macklem Says -- Market Talk

6 mei 2026, 22:11 UTC

Winsten

Taseko Mines Ltd. 1Q Adj EPS C$0.08 >TKO.LN

6 mei 2026, 22:11 UTC

Winsten

Taseko Mines Ltd. 1Q EPS C$0.05 >TKO.LN

6 mei 2026, 22:05 UTC

Marktinformatie

Updated Govt Fiscal Plan Won't Have Sizable Impact on BOC Outlook -- Market Talk

6 mei 2026, 21:58 UTC

Winsten

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6 mei 2026, 21:47 UTC

Marktinformatie

Winsten

Costco Posts 13% Sales Growth in April -- Market Talk

6 mei 2026, 21:46 UTC

Winsten

IonQ Doubles Down on Nvidia Comparison. Why the Stock Is Falling After Blowout Earnings. -- Barrons.com

6 mei 2026, 21:40 UTC

Winsten

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6 mei 2026, 21:35 UTC

Marktinformatie

BOC's Macklem Defends Warning About Rate Hikes to Fight Inflation -- Market Talk

6 mei 2026, 21:32 UTC

Populaire aandelen

Stocks to Watch Wednesday Recap: Advanced Micro Devices, Flutter, Disney, Uber -- WSJ

6 mei 2026, 21:29 UTC

Winsten

Fastly Stock Tumbles. An Earnings Beat Pauses a Monster Rally. -- Barrons.com

Peer Vergelijking

Prijswijziging

CareDx Inc Prognose

Koersdoel

By TipRanks

17.99% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 24.73 USD 17.99%

Hoogste 28 USD

Laagste 21 USD

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor CareDx Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

6 ratings

Buy

Hold

Sell

Gebaseerd op 6 analisten die aandelenratings hebben gegeven aan CareDx Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

14.77 / 18.49Steun & Weerstand

The bullish and bearish events are balanced.

All events are bearish.

Bearish events outweigh bullish events.

Sentiment

By Acuity

65 / 347 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over CareDx Inc

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.